120 related articles for article (PubMed ID: 27647403)
1. [Clinical significance of combined detection of urine NTX and serum ICTP for breast cancer patients with bone metastases].
Wu CJ; Ma LX; Zhu J; Liu JJ; Cheng Y
Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):693-7. PubMed ID: 27647403
[TBL] [Abstract][Full Text] [Related]
2. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
3. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.
Jakob C; Zavrski I; Heider U; Brux B; Eucker J; Langelotz C; Sinha P; Possinger K; Sezer O
Eur J Haematol; 2002 Jul; 69(1):37-42. PubMed ID: 12270060
[TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
[TBL] [Abstract][Full Text] [Related]
6. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
[TBL] [Abstract][Full Text] [Related]
7. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
8. Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Kishimoto K; Nakada J; Yoshihiro A; Harada J
Metabolism; 2002 Jul; 51(7):814-8. PubMed ID: 12077723
[TBL] [Abstract][Full Text] [Related]
9. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of bone metabolic markers in breast cancer with bone metastasis.
Wada N; Fujisaki M; Ishii S; Ikeda T; Kitajima M
Breast Cancer; 2001; 8(2):131-7. PubMed ID: 11342986
[TBL] [Abstract][Full Text] [Related]
11. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.
Abildgaard N; Brixen K; Kristensen JE; Eriksen EF; Nielsen JL; Heickendorff L
Br J Haematol; 2003 Jan; 120(2):235-42. PubMed ID: 12542480
[TBL] [Abstract][Full Text] [Related]
12. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
Koizumi M; Matsumoto S; Takahashi S; Yamashita T; Ogata E
Clin Nucl Med; 1999 Jan; 24(1):15-20. PubMed ID: 9890487
[TBL] [Abstract][Full Text] [Related]
13. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic validity of bone metabolic markers for bone metastasis.
Miura H; Yamamoto I; Takada M; Kigami Y; Ohta T; Yuu I; Hamanaka Y; Matsushita R; Morita R
Endocr J; 1997 Oct; 44(5):751-7. PubMed ID: 9466334
[TBL] [Abstract][Full Text] [Related]
15. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of the ratio of serum beta-CTX/PINP in multiple myeloma bone diseases and bone metastases].
Yang SW; Ma RJ; Zhao JJ; Yuan XL; Jiang L; Yang J; Lei PC; Zhang Y; Zhang L; Liu G; Wang F; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2583-2587. PubMed ID: 30220144
[No Abstract] [Full Text] [Related]
17. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
[TBL] [Abstract][Full Text] [Related]
18. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].
Xin Y; Han B; Lou J; Wu J; Niu Y
Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):947-53. PubMed ID: 20959067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
